Acrivon Therapeutics, Inc. (NASDAQ: ACRV) had its "outperform" rating re-affirmed by analysts at BMO Capital Markets. They now have a $25.00 price target on the stock.
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) had its price target raised by analysts at HC Wainwright from $20.00 to $22.00. They now have a "buy" rating on the stock.
Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights [Yahoo! Finance]
Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
Is a Surprise Coming for Acrivon Therapeutics (ACRV) This Earnings Season? [Yahoo! Finance]